The mechanism of USP7 inhibition and the resulting decrease in viability of human cancer cells in vitro are published in Chemistry & Biology
Paris, 24 April 2012 – Hybrigenics (ALHYG), a bio-pharmaceutical company l [...]
Paris, March 29, 2012 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, toda [...]
Paris, March 27, 2012 - Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases announc [...]
adds a second proprietary technology to leverage the power of the SIMPLE Antibody™platform
Rotterdam, the Netherlands and Ghent, Belgium March 19, 2012–arGEN-X announces today the launch of NHance™, its latest c [...]
Former VP Corporate Development Genzyme joins as CBO
Ghent, Belgium, 16 March 2012 - Pronota NV, the developer of first-in-class diagnostics for early detection of life-threatening conditions, has appointed Carol Grev [...]
Basel, Switzerland – 14 March 2012 – Okairos today announced the initiation of a Phase I/II clinical trial evaluating its vaccine against the hepatitis C virus (HCV). This is the first multi-center, double blinded, r [...]
The French drug agency approves a Phase II study of oral inecalcitol in CLL, an orphan disease characterized by the cancerous proliferation of white blood cells
Hybrigenics raised EUR 1.85 million in a private placeme [...]
Amsterdam, March 1, 2012
Iris Sample Processing, a division of IRIS International and KREATECH Diagnostics sign distribution agreement for novel automated FISH sample preparation in Europe and North America
· Uniq [...]
The mechanism of USP7 inhibition and the resulting decrease in viability of human cancer cells in vitro are published in Chemistry & Biology
Paris, 24 April 2012 – Hybrigenics (ALHYG), a bio-pharmaceutical company l [...]
Paris, March 29, 2012 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, toda [...]
Paris, March 27, 2012 - Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases announc [...]
adds a second proprietary technology to leverage the power of the SIMPLE Antibody™platform
Rotterdam, the Netherlands and Ghent, Belgium March 19, 2012–arGEN-X announces today the launch of NHance™, its latest c [...]
Former VP Corporate Development Genzyme joins as CBO
Ghent, Belgium, 16 March 2012 - Pronota NV, the developer of first-in-class diagnostics for early detection of life-threatening conditions, has appointed Carol Grev [...]
Basel, Switzerland – 14 March 2012 – Okairos today announced the initiation of a Phase I/II clinical trial evaluating its vaccine against the hepatitis C virus (HCV). This is the first multi-center, double blinded, r [...]
The French drug agency approves a Phase II study of oral inecalcitol in CLL, an orphan disease characterized by the cancerous proliferation of white blood cells
Hybrigenics raised EUR 1.85 million in a private placeme [...]
Amsterdam, March 1, 2012
Iris Sample Processing, a division of IRIS International and KREATECH Diagnostics sign distribution agreement for novel automated FISH sample preparation in Europe and North America
· Uniq [...]
Follow us
